Chimeric Therapeutics Reports Additional Complete Responses in CORE-NK Phase 1B AML Trial.

Chimeric Therapeutics (ASX: CHM) has announced encouraging new clinical and translational data from its ADVENT-AML Phase 1B trial, presented at the Society of Hematology Oncology Annual Meeting in Houston. The study is evaluating CORE-NK cell therapy in combination with standard AML treatment, azacitidine and venetoclax. In the dose escalation phase, six relapsed or refractory AML patients were treated with no dose-limiting toxicities, showing safety and persistence of CORE-NK cells. One patient achieved a complete response.

In the frontline high-risk AML cohort, seven evaluable patients have been treated, with four showing clinical responses, including two complete responses, one complete response with incomplete count recovery, and one partial response. Importantly, the therapy continues to be well tolerated, with no unexpected safety issues reported. With safety established, the trial has expanded to enroll up to 20 newly diagnosed patients, offering potential breakthrough treatment options in AML.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com